Denovo Biopharma







01/2020 Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications

12/2019 Denovo Biopharma Licenses Global Rights to a Novel Late-Stage Oncology Drug from Sunesis Pharmaceuticals

10/2019 Denovo Biopharma Receives FDA's Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)

06/2019 Denovo Biopharma Receives Global Rights to a Novel Late-Stage Drug for Alzheimer’s Disease from Orion Corporation for Development as a Personalized Medicine

05/2019 Three DB102 (Enzastaurin) Presentations at ASCO and the 15th International Conference on Malignant Lymphoma (ICML)

02/2019 Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance

11/2018 Two Posters on DB102 (Enzastaurin) Presented at the American Society of Hematology Annual Meeting

11/2018 Speedy China IND approval as Denovo takes aim at large schizophrenia market (BioWorld Cover Story)

10/2018 Denovo Biopharma to Participate at Morgan Stanley 17th Annual Asia Pacific Summit

06/2018 Denovo Biopharma Acquires Exclusive License of Novel Application of DB102 in the Treatment of Pulmonary Arterial Hypertension

05/2018 Denovo Biopharma to Participate in Jefferies 2018 Global Healthcare Conference

05/2018 Denovo Biopharma to Participate at Morgan Stanley 4th Annual China Summit

04/2018 Denovo kicks off phase III biomarker-driven trial in DLBCL; doses first patient in China (BioWorld Top Line News)

04/2018 First Patient Dosed in Pivotal Biomarker-Guided Phase 3 Study of First Line Therapy with DB102 (enzastaurin) + R-CHOP in Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

01/2018 San Diego's Denovo Biopharma Opens Doors to New R&D Center, Names New CMO and CFO